-
Posted by
Two Blokes Apr 16 -
Filed in
Stock
-
2 views
Regeneron's stock has dropped 40% due to EYLEA's IP issues, but strong financials and pipeline assets bolster optimism for long-term growth. Dupixent's robust sales growth and potential new indications position it as Regeneron's primary growth engine, overshadowing EYLEA. Regeneron's oncology platform, led by Libtayo and promising bispecific antibodies, is poised to be a significant growth driver in the next decade.
